SHILPAMED vs WINDLAS: Stock Comparison
SHILPA MEDICARE is the larger company by market capitalisation. SHILPA MEDICARE shows faster revenue growth and a higher net margin, while WINDLAS BIOTECH shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SHILPAMED leads 4; WINDLAS leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| Live Price | ₹961.15 | ₹1,129.25 |
| Day Change | 2.26% | -0.01% |
| Volume | 14.72 L | 66,749 |
| 52-Week High | ₹980.1 | ₹1,181.9 |
| 52-Week Low | ₹259.5 | ₹697.4 |
| Distance from 52W High | -1.93% | -4.45% |
Valuation
| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| Market Cap | ₹18,835 Cr | ₹2,359 Cr |
| P/E Ratio | 63.36x | 49.39x |
| P/B Ratio | 7.27x | 4.15x |
| EPS | ₹3.32 | ₹8.55 |
| Book Value | ₹132.49 | ₹281.47 |
| Dividend Yield | 0.17% | 0.55% |
Growth
| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| Revenue Growth (TTM YoY) | 31.5% | 17.7% |
| EPS Growth (TTM YoY) | 644.6% | -2.6% |
| Qtr Sales Growth | -59.41% | 4.03% |
| Qtr Profit Growth | -35.65% | 10.22% |
Profitability & Leverage
| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| ROE | 4.9% | 11.44% |
| ROCE | 5.01% | 11.95% |
| Net Margin | 15.82% | 7.35% |
| Operating Margin | 26.49% | 10.15% |
| Debt to Equity | 0.05x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | SHILPAMED | WINDLAS |
|---|---|---|
| Promoter Holding | 40.13% | 63.31%▲ 1.41 pp |
| FII Holding | 11.38%▲ 0.3 pp | 2.04%▲ 1.44 pp |
| DII Holding | 8.05%▼ 0.53 pp | 9.84%▼ 1.97 pp |
| Public Holding | 40.43%▲ 0.22 pp | 24.8%▼ 0.9 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHILPA MEDICARE and WINDLAS BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.